Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010 · 15,377 citations
2. 2Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer2015 · 8,649 citations
3. 3FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer2015 · 191 citations
4. 4Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer2015 · 1,200 citations
5. 5Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer2015 · 6,324 citations